Pharmacologic class: Receptor tyrosine kinase inhibitor

Therapeutic class: Antineoplastic

Pregnancy risk category D


Inhibits receptor tyrosine kinases, including ALK, hepatocyte growth factor receptor, and recepteur d'origine nantais. Translocations can affect the ALK gene, resulting in expression of oncogenic fusion proteins. Formation of ALK fusion proteins results in activation and dysregulation of the gene's expression and signaling, which can contribute to increased cell proliferation and survival in tumors expressing these proteins.


Capsules: 200 mg, 250 mg

Indications and dosages

Anaplastic lymphoma kinase-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC)

Adults: 250 mg P.O. b.i.d. Dosing interruption or reduction to 200 mg P.O. b.i.d. may be required based on individual safety and tolerability; then 250 mg P.O. daily if further reduction is necessary.

Dosage adjustment

• Hepatotoxicity

• Hematologic toxicities

• Grade 3 QT interval prolongation




Use cautiously in:

• hepatic impairment, severe renal impairment (creatinine clearance less than 30 ml/minute), end-stage renal disease

• congenital long QT syndrome (avoid use), congestive heart failure, bradyarrhythmias, electrolyte abnormalities, pulmonary disease

• concurrent use of drugs known to prolong QT interval (such as alfuzosin, amiodarone, ibutilide, or quetiapine)

• concurrent use of moderate CYP3A inhibitors

• concurrent use of strong CYP3A inducers or inhibitors (avoid use)

• concurrent use of CYP3A substrates with narrow therapeutic indices (avoid use)

• grapefruit, grapefruit juice, St. John's wort (avoid use)

• pregnant or breastfeeding patients

• children (safety and efficacy not established).


• Be aware that detection of ALK-positive NSCLC using an FDA-approved test is necessary before starting drug.

• Administer with or without food. Don't crush, dissolve, or open capsules.

Adverse reactions

CNS: headache, fatigue, dizziness, neuropathy, insomnia

CV: bradycardia, prolonged

QT interval

EENT: vision disorder

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, esophageal disorder, stomatitis

GU: complex renal cysts

Hematologic: neutropenia, thrombocytopenia, lymphopenia

Hepatic: hepatotoxicity

Musculoskeletal: arthralgia, back pain

Respiratory: upper respiratory tract infection, dyspnea, cough,

pneumonia, pulmonary embolism

Skin: rash

Other: edema, chest pain or discomfort, fever, decreased appetite, dysgeusia


Drug-drug. CYP3A substrates with narrow therapeutic indices (such as alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus): inhibited metabolism of these drugs, leading to potential for serious adverse reactions

Moderate CYP3A inhibitors (such as diltiazem): possible increased crizotinib plasma concentration

Strong CYP3A inducers (including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin): decreased crizotinib plasma concentration

Strong CYP3A inhibitors (such as atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole): increased crizotinib plasma concentration

Drug-diagnostic tests. ALT, AST: increased levels

Lymphocytes, neutrophils, platelets: decreased levels

Drug-food. Grapefruit, grapefruit juice: increased crizotinib plasma concentration

High-fat meal: decreased crizotinib area under the curve and Cmax.

Drug-herbs. St. John's wort: decreased crizotinib plasma concentration

Patient monitoring

Monitor liver function tests (including ALT and total bilirubin) monthly and as clinically indicated, with more frequent testing in patients who develop transaminase elevations. Temporarily suspend drug, reduce dosage, or permanently discontinue drug as indicated.

• Monitor CBC with differential and renal function tests closely.

Monitor patient for pulmonary signs and symptoms indicative of pneumonitis; permanently discontinue drug in patients diagnosed with treatment-related pneumonitis.

Consider periodic ECGs and electrolyte monitoring in patients who have QT-interval prolongation or predisposition for QT-interval prolongation, or who are taking drugs known to prolong QT interval. Withhold drug in patients with Grade 3 QT-interval prolongation until recovery to Grade 1 or less; then resume at prescribed reduced dosage. Permanently discontinue drug if Grade 3 QT-interval prolongation recurs and in patients with Grade 4 QT-interval prolongation.

Patient teaching

• Tell patient to take drug with or without food, to avoid grapefruit and grapefruit juice, and not to crush, dissolve, or open capsules.

Instruct patient to immediately report signs and symptoms of liver disorder (such as weakness, fatigue, nausea, vomiting, right upper abdominal pain, jaundice, yellowing of skin or eyes, or dark urine).

Instruct patient to immediately report swelling of hands or feet, abnormal heartbeats, dizziness, or faintness.

• Inform patient that visual changes, such as perceived flashes of light, blurry vision, light sensitivity, and floaters, may occur and to report flashes or floaters to prescriber.

• Caution patient to use caution while driving and performing other hazardous activities, because of the risk of developing a vision disorder, dizziness, or fatigue while taking drug.

• Instruct patient to tell prescriber about all drugs he's taking, because some drugs have potential for serious drug interactions and shouldn't be taken with crizotinib.

• Advise patient not to use St. John's wort or other herbal supplements without consulting prescriber.

• Advise female patient of childbearing age to avoid becoming pregnant during treatment.

• Advise breastfeeding patient that she should decide whether to discontinue breastfeeding or discontinue drug, taking into account importance of drug for her treatment.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


(kriz-oh-ti-nib) ,


(trade name)


Therapeutic: antineoplastics
Pharmacologic: kinase inhibitors
Pregnancy Category: D


Locally advanced/metastatic non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK).


Inhibits receptor tyrosine kinases including anaplastic lymphoma kinase (ALK), Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur d'Origine Nantais (RON).

Therapeutic effects

Decreased spread of lung cancer.


Absorption: 43% absorbed following oral administration.
Distribution: Extensively distributed to tissues.
Metabolism and Excretion: Mostly metabolized by the liver (CYP3A4/5 enzyme system) also acts as a inhibitor of CYP3A. 53% excreted in feces unchanged, 2.3% eliminated unchanged in urine.
Half-life: 42 hr.

Time/action profile (blood levels)

POunknown4–6 hrunknown


Contraindicated in: Concurrent use of strong inhibitors/inducers of the CYP3A enzyme system;Congenital long QT syndrome; Obstetric: May cause fetal harm; Lactation: Breast feeding should be avoided.
Use Cautiously in: Heart failure, bradyarrhythmias, electrolyte abnormalities, concurrent medications that prolong QT interval (↑ risk of arrhythmias);genetic implication Asian patients (↑ blood levels);Hepatic impairment;Severe renal impairment;Patients with childbearing potential; Pediatric: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Central nervous system

  • fatigue
  • headache
  • insomnia

Ear, Eye, Nose, Throat

  • visual disturbances (most frequent)


  • pneumonitis (life-threatening)


  • QTc interval prolongation (life-threatening)
  • bradycardia (most frequent)
  • edema (most frequent)
  • chest pain


  • hepatotoxicity (life-threatening)
  • constipation (most frequent)
  • diarrhea (most frequent)
  • nausea (most frequent)
  • vomiting (most frequent)
  • abdominal pain
  • dysgeusia
  • ↓ appetite
  • stomatitis


  • rash


  • neuropathy


  • fever


Drug-Drug interaction

Concurrent use of strong CYP3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, and voriconazole may ↑ levels and should be avoided.Concurrent use of strong CYP3A inducers including carbamazepine, phenobarbital, phenytoin, rifabutin, and rifampin may ↓ levels and effectiveness and should be avoided.Antacids, H2 blockers, and proton pump inhibitors may ↓ levelsBeta-blockes, verapamil, diltiazem, digoxin, and clonidine may ↑ risk of bradycardia; avoid concurrent use, if possibleConcurrent use of St. John's wort may ↓ levels and effectiveness and should be avoided.Grapefruit or grapefruit juice may ↑ levels and should be avoided.


Oral (Adults) 250 mg twice daily; dose adjusted according to tolerance, toxicity or adverse effects.

Renal Impairment

Oral (Adults) CCr <30 mL/min (not on dialysis)—250 mg once daily


Capsules: 200 mg, 250 mg

Nursing implications

Nursing assessment

  • Assess respiratory function (lung sounds, dyspnea, oxygen saturation) periodically during therapy.
  • Monitor for signs and symptoms of pneumonitis (difficulty breathing, shortness or breath, cough with or without mucus, fever) periodically during therapy. If any Grade of pneumonitis occurs, permanently discontinue.
  • Assess for signs and symptoms of neuropathy (burning, dysesthesia, hyperesthesia, hypoesthesia, neuralgia, paresthesia, peripheral neuropathy sensory and motor) periodically during therapy. Usually Grade 1.
  • Monitor ECG periodically during therapy in patients with HF, bradyarrhythmias, electrolyte imbalances, or taking medications than may prolong QT interval. If Grade 3 QTc prolongation occurs, withhold until recovery to Grade ≤1, then resume at 200 mg twice daily. If Grade 4 QTc prolongation occurs, permanently discontinue. If symptomatic bradycardia occurs, withhold dose until heart rate return to ≥60 bpm. Evaluate concomitant medications, if contributing medication is identified and dose reduced or discontinued, return to previous dose of crizotinib once heart rate is ≥60 bpm and/or bradycardia is asymptomatic. If no contributing medication is identified or dose modifications are not made, resume crizotinib at a reduced dose once heart rate ≥60 bpm and/or bradycardia is asymptomatic. If bradycardia is life-threatening and no contributing medication identified, discontinue crizotinib. If contributing medication is identified and dose is reduced or discontinued, reduce crizotinib dose to 250 mg once daily with frequent monitoring once heart rate ≥60 bpm and/or bradycardia is asymptomatic.
  • Lab Test Considerations: Monitor CBC with differential monthly and as clinically indicated; more frequently if Grade 3 or 4 toxicities occur. If Grade 3 hematologic toxicity occurs, withhold dose until recovery to Grade ≤2, then resume same dose schedule. If Grade 4 hematologic toxicity occurs, withhold until recovery to Grade ≤2, then resume at 200 mg twice daily. May also cause Grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia.
    • Monitor liver function tests monthly and as clinically indicated; more frequently if Grade 2, 3, 4 abnormalities occur. If Grade 3 or 4 AST or ALT ↑ with Grade ≤1 total bilirubin occurs, withhold until recovery to Grade ≤1 or baseline, then resume at 200 mg twice daily. If Grade 2, 3, or 4 AST or ALT ↑ with concurrent Grade 2, 3, or 4 total bilirubin ↑ (with no cholestasis or hemolysis), permanently discontinue.

Potential Nursing Diagnoses

Impaired gas exchange (Indications)


  • Oral: Administer twice daily without regard to food. Swallow capsules whole, do not crush, dissolve, or open.

Patient/Family Teaching

  • Instruct patient to take crizotinib as directed; do not change dose or stop taking without consulting health care professional. Take missed doses as soon as remembered unless <6 hr until next dose. If <6 hr to next dose, skip dose and return to regular schedule; do not double doses. Advise patient to read the Patient Information leaflet before starting and with each Rx refill in case of changes.
  • Advise patient to avoid eating grapefruit or drinking grapefruit juice during therapy.
  • Caution patient that dizziness and visual disorders may occur. Advise patient to avoid driving or other activities requiring alertness until response to medication is known. Visual disturbances generally start within 2 wk of therapy. Instruct patient to notify health care professional if flashes of light or new or worse vitreous floaters occur; ophthalmological evaluation should be considered.
  • Advise patient to notify health care professional immediately if symptoms of weakness, fatigue, anorexia, nausea, vomiting, abdominal pain (especially RUQ abdominal pain), jaundice, dark urine, generalized pruritus, and bleeding occur, especially in combination with fever and rash
  • Inform patient that nausea, diarrhea, vomiting, and constipation are common side effects. Standard anti-emetic, antidiarrheal, and laxative medications are usually effective.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
  • Instruct women of childbearing age and their partners to use effective contraception during and for at least 90 days following discontinuation of therapy and to avoid breast feeding during therapy.

Evaluation/Desired Outcomes

  • Decrease spread of lung cancer.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
The findings published in the journal 'Oncogene' highlighted that breast cancer drug palbociclib when combined with the lung cancer drug crizotinib, yielded better results and the combination of the two was more effective against cancer cells in the laboratory than their solo use.
Within the ROS1+ NSCLC blinded independent central review, or BICR, efficacy evaluable population, the median number of prior TKI therapies was one, the majority of which were crizotinib. Forty-five percent of patients remained on treatment, with 12 of the 15 patients remaining on treatment for more than 12 months.
The European Commission has granted conditional marketing authorisation for Pfizer's LORVIQUA as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy, or crizotinib and at least one other ALK TKI, it was reported yesterday.
15, 2018 (HealthDay News) -- Among patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor, progression-free survival is significantly longer in those who receive treatment with brigatinib versus crizotinib, according to a study published online Sept.
As with EGFR-targeted TKIs, there has been significant progress made in overcoming resistance to the first TKI approved to target activating ALK fusion mutations in metastatic NSCLC patients, crizotinib. The drugs ceritinib, alectinib, and brigatinib are all currently Food and Drug Administration-approved for this indication, as they have all shown efficacy in patients who stop responding to crizotinib.
To the Editor: Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a common complication in cancer patients, and the overall risk of VTE in patients with a malignancy was 7-fold as high as that for patients without cancer.[1] Herein, we report a case of long-term survival associated with crizotinib in an anaplastic lymphoma kinase (ALK)-positive lung cancer patient with a pulmonary artery embolism.
Crizotinib is a small-molecule inhibitor of the protooncogene receptor tyrosine kinases anaplastic lymphoma kinase (ALK), ROS1, and MET.
Developed by Pfizer Co., crizotinib was a potent and selective small-molecule dual inhibitor of the mesenchymal-epithelial transition factor (c-Met) kinase and anaplastic lymphoma kinase (ALK), possessing effective tumor growth inhibition and good pharmaceutical properties.
Treatment with a MET inhibitor such as crizotinib is a promising strategy for patients with this mutation.
Crizotinib has been approved for a rare form of the disease - ALK+ advanced non-small cell lung cancer - where cells contain defects affecting a gene responsible for a key protein.
We expect to begin a clinical trial early this year, Mosse noted The researchers found that the new drug can treat some forms of neuroblastoma that resist the anti-cancer drug crizotinib.